Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease

• 資料種別: 記事
• タイトル: Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease
• 著者標目: Fujimoto Shodai; Katsurada Naoko; Hazama Daisuke; Yamamoto Masatsugu; Nagano Tatusya; Tachihara Motoko
• 出版年月日等: 2025-03-01
• 出版年（W3CDTF）: 2025-03-01
• タイトル（掲載誌）: Internal Medicine
• 巻号年月日等（掲載誌）: 64 5
• 掲載巻: 64
• 掲載号: 5
• 掲載ページ: 749-751
• 掲載年月日（W3CDTF）: 2025-03-01
• ISSN（掲載誌）: 09182918
• 出版事項（掲載誌）: The Japanese Society of Internal Medicine
• 本文の言語コード: en
• 件名標目: ramucirumab; erlotinib; osimertinib; drug-induced interstitial lung disease; lung adenocarcinoma
• 対象利用者: 一般
• 標準番号（その他）: PMID : 39048364
• DOI: 10.2169/internalmedicine.3932-24; https://doi.org/10.2169/internalmedicine.3932-24
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（URI）: https://hdl.handle.net/20.500.14094/0100495744; https://www.jstage.jst.go.jp/article/internalmedicine/64/5/64_3932-24/_pdf; https://search.jamas.or.jp/link/ui/2025345518
• 参照: Successful Switch to Afatinib and Osimertinib Rechallenge with Corticosteroids after Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review; https://cir.nii.ac.jp/crid/1390305201349328640
• 参照: Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor; https://cir.nii.ac.jp/crid/1360009142797436032; A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy; https://cir.nii.ac.jp/crid/1360011145245520768; Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer; https://cir.nii.ac.jp/crid/1360017285912608512; Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease; https://cir.nii.ac.jp/crid/1360019692625734400; Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients; https://cir.nii.ac.jp/crid/1360292619055983232; Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC; https://cir.nii.ac.jp/crid/1360292620305878400; RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability; https://cir.nii.ac.jp/crid/1360301165364230528; Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study; https://cir.nii.ac.jp/crid/1360582250161153792; Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study; https://cir.nii.ac.jp/crid/1360582250164615552; Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis; https://cir.nii.ac.jp/crid/1360846641966345344; Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset; https://cir.nii.ac.jp/crid/1360864116842740352; Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study; https://cir.nii.ac.jp/crid/1360864116870730240; Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer; https://cir.nii.ac.jp/crid/1361418518556631040; Nintedanib in Progressive Fibrosing Interstitial Lung Diseases; https://cir.nii.ac.jp/crid/1361699995855582336; Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset; https://cir.nii.ac.jp/crid/1362262943667966336
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; 学術機関リポジトリデータベース; https://irdb.nii.ac.jp; Crossref; https://www.crossref.org; PubMed; https://pubmed.ncbi.nlm.nih.gov

• 要約等: <p>Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs for patients with EGFR mutation-positive non-small cell lun...